Advanced Search

 

Study ID Status Title Patient Level Data
S3B30048 Completed A 12-Week, Randomized, Double-Blind, Placebo- Controlled Study of PRN BID and Fixed Dosing Regimens of Alosetron in Female Subjects with Severe Diarrhea-Predominant Irritable Bowel Syndrome Who Have Failed Conventional Therapy
S3B40031 Completed A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Alosetron Hydrochloride 1mg Twice Daily for Control of Bowel Urgency in Females with Non-constipated Irritable Bowel Syndrome in an Independent Practitioner Association (IPA) Model
S3B40032 Completed An Observational Study to Assess Prevalence, Natural History, and Burden of Illness of Irritable Bowel Syndrome (IBS) in Clinical Practice and to Evaluate the Impact of Alosetron Treatment on Natural History and Burden of Illness in a Cohort of Females Whose Predominant Bowel Symptom is Diarrhea
S3B40040 Completed A Double-Blind, Placebo-Controlled, Randomised, 2-Way Crossover Study to Evaluate the Potential Inhibition of Alosetron Metabolism by Ketoconazole in Healthy Female Subjects
S3B40041 Completed A Double-Blind, Placebo-Controlled, Randomised, 2-Way Crossover Study to Evaluate the Potential Inhibition of Alosetron Metabolism by Fluvoxamine in Healthy Female Subjects
S3B40042 Completed A randomize, placebo-controlled, crossover study to measure the effect of alosetron on mucosal blood flow in female healthy volunteers and diarrhea-predominant IBS subjects
S3BA1001 Completed A Randomised, Placebo-Controlled, Repeat Dose, Double-Blind Two-Period, Cross-over Study to Compare ECG Changes and Pharmacokinetics of Cisapride Following 4 Days of Dosing With Cisapride 20mg QID with Placebo and with Alosetron 1mg BID in Healthy Male and Female Volunteers.
S3BA1002 Completed An Open-Label, Non-Randomized, Two-Period Crossover, Drug-Drug Interaction Study to Compare the Pharmacokinetics of MIN-OVRAL in Healthy Female Subjects When Administered Alone for 21 Days, and Following Co-Administration of Alosetron 1mg bid Orally for 21 Days.
S3BA1003 Completed A randomised, open label, two-way cross-over trial to evaluate colonic transit times following one week of mebeverine 135 mg tds plus alosetron 1 mg bd versus alosetron 1 mg bd in healthy female volunteers.
S3BA1004 Completed A Randomized, Double-Blind, Placebo-Controlled, Repeat Dose, Two Period, Crossover Study to evaluate the effect of alosetron (1mg po BID) on theophylline (THEO-DUR 200mg po BID) pharmacokinetics in healthy female volunteers.
S3BA1006 Completed A Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study to Determine the Effect of Alosetron 1mg BID on Cholecystokinin-Induced Colonic Motility and Abdominal Pain in IBS Patients
S3BA2001 Completed A 12-week, Dose-ranging, Double-blind, Placebo-controlled Study of Alosetron (GR68755) in Subjects with Irritable Bowel Syndrome
S3BA2002 Completed Characterization of Changes in Regional Brain Activity Associated With Sigmoid Sensitization in IBS Patients Using Positron Emission Tomography (PET) With and Without Alosetron Therapy
S3BA3001 Completed A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Alosetron (GR68755) in Female Subjects With Irritable Bowel Syndrome
S3BA3002 Completed A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Alosetron (GR68755) in Female Subjects With Irritable Bowel Syndrome
S3BA3003 Completed A 12-Month Randomized, Double-blind, Placebo-controlled Study to Evaluate the Quality of Life and Safety Associated with the Long-term Use of Alosetron (GR68755) in Subjects with Irritable Bowel Syndrome (Final Analysis)
S3BB1002 Completed A Study to Investigate the Effect of Alosetron (4mg), BID for 7½ Days, on 24-Hour Small Bowel Motility, in Patients With Irritable Bowel Syndrome (IBS)
S3BB1004 Completed A study to determine the effects of food on the pharmacokinetics of oral alosetron in healthy volunteers.
S3BB1010 Completed Report of a study to compare the pharmacokinetics of, and tolerability to, a single, oral, 1 mg dose of alosetron in healthy subjects and subjects with renal impairment not requiring dialysis.
S3BB1011 Completed The pharmacokinetics of alosetron 1 mg bid oral administration for 29 days in healthy subjects.
S3BB2009 Completed A Double-Blind Placebo-Controlled Study to Determine the Efficacy of GR68755C (Alosetron) in Treatment of Irritable Bowel Syndrome
S3BB2011 Completed A study to investigate the effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome (IBS).
S3BB3001 Completed A Multicentre, Randomised, Double-blind Comparison of Alosetron 1mg bd against Mebeverine 135mg tds for 12 Weeks in the Treatment of Female Patients with Irritable Bowel Syndrome
S3BB3002 Completed A Multicentre, Randomised, Double-Blind Comparison of Alosetron 1mg bd against Trimebutine 200mg tds for 12 weeks in the Treatment of Female Patients with Irritable Bowel Syndrome.
S3GK01 Completed A Study to Determine the Pharmacokinetics of Orally Administered Ondansetron 16mg in Patients Having Surgery Under General Anaesthesia

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.